Association of ACE ID, MTHFR C677T, and MIF-173GC variants with the clinical course of COVID-19 patients.

The course of coronavirus disease-2019 (COVID-19) differs from person to person. The relationship between the genetic variations of the host and the course of COVID-19 has been a matter of interest. In this study, we investigated whether Angiotensin-Converting Enzyme (ACE) ID, Methylenetetrahydrofolate Reductase (MTHFR) C677T, and Macrophage Migration Inhibitory Factor (MIF)-173GC variants are risk factors for the clinical course of COVID-19 disease in Turkish patients. One hundred COVID-19 patients were included in the study. The diagnosis of COVID-19 was made using Reverse Transcription Polymerase Chain Reaction (RT-PCR) and Chest Computed Tomography (CT). The patients were evaluated in 3 groups: intensive care, service, and outpatient treatment. ACE ID, MTHFR C677T, and MIF-173GC variants were genotyped by PCR-Restriction Fragment Length Polymorphism (RFLP) methods. When the genotype distribution between the groups was examined, it was found that the frequency of the ACE DD genotype and the D allele was higher in the intensive care group compared to the hospitalized and outpatient groups. MTHFR C677T CT genotype T allele and MIF-173GC, CC genotype C allele were more prevalent in the intensive care group compared to other groups. Patients with PCR-positive results had a higher MTHFR C677T C/C genotype and C allele. In CT-positive patients, the MTHFR C677T CT genotype and the MIF-173GC, G allele were more common. It is predicted that genetic predisposition may contribute to COVID-19 morbidity and mortality. Our results show that ACE ID, MTHFR C677T, and MIF-173GC variants affect the course of COVID-19 disease in the Turkish population.

Trueness and marginal fit of implant-supported complete-arch fixed prosthesis frameworks made of high-performance polymers and titanium: An explorative in-vitro study.

PURPOSE: To investigate the trueness and marginal fit of computer-aided design-computer-aided manufactured (CAD-CAM) complete-arch implant-supported screw-retained fixed prosthesis (CAISFP) made of polyetheretherketone (PEEK), polyetherketoneketone (PEKK) and titanium (Ti) MATERIAL AND METHODS: A typodont model with four implants, their multiunit abutments (MUAs), and MUA scanbodies were digitized by using a laboratory scanner. The generated CAD was used to mill CAISFP frameworks in Ti, PEEK, or PEKK (each n = 10). The frameworks were digitized with an industrial light scanner to superimpose resulting standard tessellation language (STL) file with the CAD file. Deviations at five points at the abutment-framework interface of each of the four abutment sites (1:left first molar, 2:left canine, 3:right canine, 4:right first molar sites) were calculated (trueness). Marginal gaps were measured using the triple scan technique. A nonparametric repeated measures ANOVA by Brunner and Puri with factors being abutment location and material was performed to assess the mean deviations for trueness and mean marginal gaps, followed by Mann-Whitney or exact Wilcoxon Signed-Rank tests (alpha=.05). RESULTS: Material type significantly affected the trueness (p<0.0001). PEEK had the lowest deviations (0.039 +/-0.01mm) followed by PEKK (0,049 +/-0.009mm), and Ti (0.074 +/-0.011mm). For marginal gaps, only abutment location's effect was significant (p = 0.003). Within PEKK, gaps at abutment 4 were significantly larger, compared with abutments 2 (p = 0.04) and 3 (p = 0.02). CONCLUSIONS: The trueness of PEEK, PEKK, and Ti frameworks was different after milled. PEEK had the highest trueness. However, the marginal fit of the frameworks was similar and smaller than 90 µm in average. CLINICAL RELEVANCE: PEEK, PEKK, and Ti complete-arch frameworks had clinically acceptable gaps and may therefore be recommended when their fit is considered. Higher trueness after milling did not result in better marginal fit.

Effectiveness of ozone therapy in addition to conventional treatment on mortality in patients with COVID-19.

AIM: In this study, we aimed to investigate the effectiveness of ozone therapy, which is one of the integrative medicine applications that has been used safely for many years, on the prevalence of mortality in patients receiving COVID-19 treatment. METHODS: This was a prospective, controlled study conducted on patients with COVID-19 who were hospitalised. In this study, 55 patients were included. The patients were divided into two groups as the ozone and control group. Ozone therapy (major autohemotherapy) was applied to 37 patients who were being treated with the appropriate COVID-19 treatment protocol determined by the infectious diseases committee of our hospital. The ozone treatment protocol consisted of seven sessions (one session per day) of intravenous ozone administration, applied in a volume of 100 mL and a concentration of 30 µg/mL. Only the conventional COVID-19 treatment protocol was applied to 18 patients in the control group. Clinical follow-up was performed until the discharge of the patients from the hospital with successful treatment or until the mortality occurred. Factors affecting mortality were analysed using univariate regression analysis. RESULTS: Intensive care unit (ICU) hospitalisation was required in 6 of the 37 patients who were treated with ozone (16.2%), while 4 of 18 patients in the control group required ICU treatment (22.2%) (P = .713). When the mortality rates between the two groups were compared, mortality was lower in the ozone group (P = .032). As a result of univariate logistic regression analysis performed to investigate the factors affecting mortality, treatment with ozone therapy was determined as a risk factor for mortality. Patients receiving ozone therapy appear to have a lower mortality risk (odds ratio [OR]: 0.149, 95% confidence interval [CI] 0.026-0.863, P = .034). CONCLUSION: In this study, the findings suggested that the administration of ozone therapy along with the conventional medical treatment in patients hospitalised for COVID-19 could reduce mortality.

Importance of CT scans in diagnosing symptoms from misplaced implants.

Maxillary sinus or nasal cavity invasion with implants might not be detected during implant placement. However, these complications cause problems in the long run. In the following two cases, maxillary sinus and nasal cavity invasion with misplaced implants could not be detected with panoramic and periapical radiographs; the patients had to undergo several prosthetic and surgical procedures to have their problems resolved. These problems were detected with CT imaging technique. For the first patient, the misplaced implant was removed and a new prosthesis was fabricated on the remaining implants. The prosthetic treatment of the second patient was finalized with new implants placed in the removed implant sites, and a new metal-resin implant-fixed complete dental prosthesis was fabricated.